{"groups":[{"description":"Participants with Gastric-GEJ cancer \\[Second-Third Line (L)\\] received 8 milligrams per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 for every 3 weeks (Q3W) of a 21-day cycle.","id":"FG000","title":"Cohort A"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG002","title":"Cohort A2"},{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG003","title":"Cohort B"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG004","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG005","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"FG006","title":"Cohort E"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"17"},{"groupId":"FG006","numSubjects":"10"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"Enrolled but Never Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"17"},{"groupId":"FG004","numSubjects":"28"},{"groupId":"FG005","numSubjects":"24"},{"groupId":"FG006","numSubjects":"27"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"17"},{"groupId":"FG004","numSubjects":"27"},{"groupId":"FG005","numSubjects":"24"},{"groupId":"FG006","numSubjects":"26"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Phase 1a"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"17"},{"groupId":"FG004","numSubjects":"24"},{"groupId":"FG005","numSubjects":"24"},{"groupId":"FG006","numSubjects":"26"}],"type":"Phase 1b"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"24"},{"groupId":"FG006","numSubjects":"19"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants who did not \"complete\" study were those who discontinued study treatment by the time of study completion.","recruitmentDetails":"This study has Phase 1a (dose-limiting toxicity \\[DLT\\] observation) and expansion Phase 1b (safety and preliminary efficacy) included participants with 2 dosing schedules:\n\nSchedule 1: gastroesophageal junction (GEJ) cancer (Cohorts A, A2) and biliary tract cancer (Cohorts A1); Schedule 2: Gastric-GEJ cancer (Cohort B), nonsmall cell lung cancer (NSCLC) (Cohorts C, E), and urothelial cancer (Cohort D)."}